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Abstract 
Hypertension (HTN) is a significant risk factor for cardiovascular morbidity and mortality. 
Metabolic abnormalities, including adverse cholesterol and triglycerides (TG) profiles, 
are frequent comorbid findings with HTN and contribute to cardiovascular disease. 
Diuretics, which are used to treat HTN and heart failure, have been associated with 
worsening of fasting lipid concentrations. A genome-wide meta-analyses with 39 710 
European-ancestry (EA) individuals and 9 925 African-ancestry (AA) individuals was 
performed to identify genetic variants that modify the effect of loop or thiazide diuretic 
use on blood lipid concentrations. Both longitudinal and cross-sectional data were used 
to compute cohort-specific interaction results, which were then combined through meta-
analysis in each ancestry. These ancestry-specific results were further combined 
through trans-ancestry meta-analysis. Analysis of EA data identified 6 genome-wide 
significant (p < 5•10-8) variants (in 2 loci) with loop diuretic-SNP interaction on TG 
concentrations (including 5 variants in COL11A1). Analysis of AA data identified 9 
genome-wide significant variants (in one locus adjacent to BMP2) with loop diuretic-
SNP interaction on TG concentrations. Trans-ancestry analysis strengthened evidence 
of association at two loci from suggestive to genome-wide significant (KIAA1217 and 
BAALC). There were few significant diuretic-SNP interaction associations for thiazide 
diuretics on TG concentrations and for either diuretic on cholesterol concentrations. 
Several promising loci were identified that may implicate biologic pathways that 
contribute to adverse metabolic side effects from diuretic therapy. 
  
 Page 5 of 35 
 
Introduction 
Hypertension (HTN) is a significant risk factor for cardiovascular morbidity and mortality. 
However, even after accounting for the beneficial effects of blood pressure reduction on 
cardiovascular events, cardiovascular risk remains elevated despite intensive blood 
pressure lowering.1 Metabolic abnormalities, including adverse cholesterol and 
triglycerides (TG) profiles, are frequent comorbid findings with HTN and may contribute 
to the residual cardiovascular disease (CVD) risk associated with antihypertensive 
therapy. Thiazide diuretics are recommended as first-line therapy for the treatment of 
HTN.2 Loop diuretics are a mainstay in the treatment of heart failure and are frequently 
used in patients with hypertension complicated by renal insufficiency to control volume 
retention. However, there is little evidence to support a survival benefit with the use of 
loop diuretics.3 Both thiazide and loop diuretics have been associated with worsening 
fasting lipid concentrations,4-6 which may dampen the salutary effects of 
antihypertensive therapy in some patients. While there have been studies identifying 
genetic sources of inter-individual blood pressure response to primarily thiazide diuretic 
therapy,31-35 there is little existing literature regarding the interactions of diuretics with 
genetic variants on blood lipid concentrations.36 
A meta-analysis of 56 randomized, placebo-controlled trials of diuretic monotherapy for 
the treatment of HTN, including both European-ancestry (EA) and African-ancestry (AA) 
individuals, showed that diuretic therapy was associated with average changes of 0.29 
mmol/L for total cholesterol (TC), 0.24 mmol/L for low-density lipoprotein cholesterol 
(LDL), -0.02 mmol/L for high-density lipoprotein cholesterol (HDL), and 0.35 mmol/L for 
TG.7 Some long-term studies have suggested that effects of diuretics on lipid 
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concentrations waned after one year.8,9 A retrospective analysis of the Systolic 
Hypertension in the Elderly Program (SHEP) showed persistent, albeit more modest, 
increases in lipid concentrations (three-year change in TG: 0.28 ± 0.86 mmol/L with 
chlorthalidone vs. 0.09 ± 0.71 mmol/L with placebo, p<0.001) when a cohort was 
randomized to a thiazide-like diuretic or a placebo;10 however, these results may have 
been affected by the use of non-diuretic antihypertensive drugs (atenolol and reserpine) 
in this study. Notably, the larger standard deviations suggest that an underlying genetic 
component may explain the high variability in individual’s lipid response to diuretic 
therapy. 
Although the genetic underpinnings of fasting cholesterol and TG concentrations have 
been well-described, single nucleotide polymorphisms (SNPs) identified through 
genome-wide association studies (GWAS) explain only ~10-12% of heritability.11 Some 
studies have shown that the response of lipid concentrations to diuretics is significantly 
greater in AA than in EA individuals,7 further suggesting the modulating effect of genetic 
architecture. Unfortunately, most long-term studies were based on either almost 
exclusively EA subjects9 or studies including individuals of multiple ancestries where 
response by ancestry was not characterized.8 The purpose of the present investigation 
was to determine whether common genetic variants modify the effect of diuretic use on 
blood lipid concentrations in persons of European and African ancestry. These analyses 
may identify biologic pathways that contribute to adverse metabolic side effects from 
diuretic therapy. 
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Materials and Methods 
Study samples, phenotype, and genotype data 
Data from 14 EA and 7 AA cohorts was used. Table 1 provides summary characteristics 
of these cohorts; a detailed description is provided in the Supplementary Materials. 
Each study obtained informed consent from participants and approval from the 
appropriate institutional review boards. Genotyping was performed using Illumina (San 
Diego, CA, USA) or Affymetrix (Santa Clara, CA, USA) genotyping arrays. Each study 
performed imputation using either HapMap Phase II data (release 22, build 36) or the 
1000 Genomes Project12 data with MACH,13 Minimac,14 IMPUTE2,15 or BEAGLE16 
software. Information on genotype and imputation for each study is presented in 
Supplementary Table 1.  
In total, 49 635 subjects over 18 years of age with genotype, phenotype, and covariate 
information were available in this analysis. Both longitudinal and cross-sectional studies 
were used, and all available data for each subject was used. In longitudinal cohorts that 
had multiple clinic visits for each subject, those multiple measurements (obtained 
across clinic visits) were used in the analysis. In cross-sectional studies that had only a 
single visit for each subject, a single measurement was used. Three fasting lipid traits 
were considered for analyses: TG, high-density lipoprotein (HDL) cholesterol, and low-
density lipoprotein (LDL) cholesterol (all mmol/L). LDL was calculated via the 
Friedewald equation (LDL=TC-HDL- [TG/5]) for those with TG <4.52 mmol/L.17 If TG 
>4.52 mmol/L, LDL was set to missing unless directly assayed. LDL concentrations 
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were adjusted for statin use as described elsewhere.18 Triglyceride concentrations were 
natural log-transformed for analysis. Two patterns of diuretic exposure were used: 1) 
thiazide and thiazide-like diuretic use (yes/no) without use of loop; and 2) loop diuretic 
use (yes/no) without use of thiazide or thiazide-like diuretics. For each diuretic 
exposure, the unexposed group consisted of individuals taking neither diuretic. Drug 
use (yes/no) is defined as the use of any drug in the drug class, regardless of dosage, 
and with or without the use of a potassium supplement, as assessed by medication 
inventory at each clinic visit.  
Statistical analyses 
To determine the association of SNP-diuretic interactions on blood cholesterol and TG 
concentrations, the following regression model 
𝔼[𝑌|𝐷, 𝐺, 𝐶] =  𝛽0 +  𝛽𝐷𝐷 +  𝛽𝐺𝐺 + 𝛽𝐺𝐷𝐺 × 𝐷 + 𝛽𝐶𝐶 
was applied. Y is the fasting lipid value, D is the diuretic use (coded 0/1 for the 
absence/presence of the diuretic), G is the dosage of the imputed genetic variant coded 
additively (from 0 to 2), and C is the vector of all other covariates, which include age, 
sex, body mass index (BMI), principal components (to account for population 
stratification and admixture), and additional cohort-specific covariates (if any). Subjects 
with missing data for fasting (≥ 8 hours) lipid values, diuretic use, or any covariate were 
excluded from analysis. Subjects taking both thiazide and loop diuretics were also 
excluded from analysis.  
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Each study conducted GWAS analysis and provided the SNP-diuretic interaction effect 
βGD and standard error. For longitudinal cohorts with repeated measures, generalized 
estimating equations (GEE) with an independent working correlation were used with an 
R package boss; for studies with cross-sectional data, linear regression was used. To 
account for relatedness in families, family studies used either GEE treating each family 
as a cluster using R software or the linear mixed effect model approach with a random 
polygenic component (for which the covariance matrix depends on the kinship matrix) 
using ProbABEL (Supplementary Table 1). Note the standardized interaction effect 
(βGD/SE) is not normally distributed when minor allele counts of SNPs among 
participants on the diuretic were small (< 10). Following our earlier work,19 cohort-
specific P-values based on a Student’s t reference distribution were computed. The 
degrees of freedom for the t-reference distribution depended on the number of drug-
exposed participants (N_exposed), the SNP imputation quality, and the minor allele 
frequency. Before meta-analysis, SNPs were excluded if 2 • MAF • N_exposed • 
imputation quality measure < 10 to exclude unstable cohort-specific results that reflect 
small sample size, low MAF, or low imputation quality measures. 
Meta-analysis for each ancestry group was performed to combine these cohort-specific 
P-values with weighted Z-statistics using METAL,20 where weights were based on the 
number of drug-exposed subjects multiplied by the SNP imputation quality. As cohort-
specific P-values were computed based on t distribution, inverse-variance weighted 
meta-analysis was not used. After meta-analysis, SNPs were excluded if they were 
available in fewer than three cohorts for EA results or two cohorts for AA results. The 
ancestry-specific results were further combined to perform trans-ancestry meta-analysis 
 Page 10 of 35 
 
using MANTRA (Meta-ANalysis of TRansethnic Association studies).21 MANTRA 
accounts for similarity in allelic effects among closely-related populations, while allowing 
for heterogeneity across populations with more diverse ancestries. As MANTRA uses a 
Bayesian framework, a traditional fixed-effect meta-analysis with weighted Z-statistics 
was also performed using METAL. 
Genome-wide significance was defined as P < 5•10-8 from METAL with a fixed-effect 
meta-analysis or Bayes Factor >105 from MANTRA, and suggestive evidence at P < 
1•10-6 for association. To assess type I error due to population stratification and other 
factors, quantile-quantile (QQ) plots were examined for all cohort-specific GWAS results 
for each pair of lipid and diuretic exposure.  In addition, during meta-analysis, genomic 
control correction22 was applied to cohort-specific GWAS results if their genomic control 
lambda value was greater than 1. The gene locations referenced in the text and tables 
were obtained from the National Center for Biotechnology Information dbSNP database 
(reference assembly GRCh38.p2). Functional annotation information was sought using 
HaploReg23 and RegulomeDB.24 
 
Results 
The European-ancestry (EA) group included 39 710 subjects from 14 cohorts; the 
African-ancestry (AA) group included 9 925 subjects from 7 cohorts (Table 1). The 
number of subjects exposed to loop diuretics was 2 117 (5.3%) in EA and 784 (7.9%) in 
AA; the number exposed to thiazide and thiazide-like diuretics was 6 878 (17.3%) in EA 
and 3 923 (39.5%) in AA.  
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The QQ plots (Supplementary Figures 1-6) showed moderate inflation, in particular for 
the loop diuretic-SNP interaction terms for TG, LDL, and HDL analyses, although the P-
values based on a t-distribution (red crosses) have better genomic control values than 
the P-values based on a standard normal distribution (black circles). Manhattan plots 
show the adjusted -log10(P) values for loop diuretics (Figures 1 and Supplementary 
Figures 7-8) and thiazide diuretics (Supplementary Figures 9-11) for TG, HDL 
cholesterol, and LDL cholesterol, respectively. Each figure includes plots of EA and AA 
separately, and for trans-ancestry meta-analysis using METAL and MANTRA. The 
SNPs reaching genome-wide significance (P < 5•10-8 from METAL or Bayes Factor 
>105 from MANTRA) for association with gene-medication interactions on TG 
concentration are shown in Table 2. Supplementary Table 2 shows the most highly 
ranked SNP-diuretic interactions by lipid trait (with P < 10-6). 
Loop diuretics with blood triglyceride (TG)  
Analysis of the EA data identified 6 SNPs (2 loci) with genome-wide significant SNP-
loop diuretic interaction effects (P < 5•10-8) on log-transformed TG concentrations 
(Figure 1). Another 33 SNPs (adding 13 loci) demonstrated a suggestive association (P 
< 1•10-6). The locus with the most promising evidence of association included a six-SNP 
cluster (most significant rs1463034, P = 1.31•10-9, βGD = 0.11 ± 0.02) spanning four 
introns (7 256 bp) in COL11A1 on chromosome 1 (Figure 2, top). Another promising 
locus included a seven-SNP cluster spanning a single intron (18 804 bp) on 
chromosome 10 in KIAA1217 (most significant rs7077598, P = 7.48•10-7). A suggestive 
locus of 12 SNPs was found at a distinct locus on chromosome 10 which is 
approximately 145 kb downstream of DKK1 (most significant rs10762762, P = 
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1.12•10-7). Within this cluster of SNPs in tight linkage disequilibrium, rs1441122 (P = 
9.33•10-7) showed moderate evidence of altering the binding motif for the transcription 
factor TRIM28 in a human embryonic kidney cell line (RegulomeDB Score 3a, 
http://www.regulomedb.org/).  
Analysis of the AA data yielded 9 SNPs (one locus) with genome-wide significant 
interaction effects on TG concentrations, with three additional SNPs (adding 2 loci) with 
suggestive P-values (Figure 1). This 10-SNP locus (most significant rs6054018, P = 
1.70•10-10, βGD = 0.21 ± 0.03; Figure 2, middle) is located in an intergenic region on 
chromosome 20 approximately 500 kb upstream of BMP2 and approximately 114 kb 
downstream of FERMT1.  
Trans-ancestry association tests strengthened evidence of association for the 
KIAA1217 locus, elevating two of the eight SNPs in this locus from suggestive in EA to 
genome-wide significance. In particular, at rs10508671, the SNP-loop diuretic 
interaction effect (βGD) was consistent in both ancestries (-0.10 vs -0.09, Supplementary 
Table 2), and therefore trans-ancestry test provided stronger evidence of association 
(EA P = 9.4•10-7, AA P = 0.003, trans-ancestry P = 1.08•10-8, MANTRA log10[BF] = 6.24, 
Figure 3, bottom). MANTRA also strengthened the association for a four-SNP locus on 
chromosome 8 (most significant rs6985929, trans-ancestry P = 9.07•10-6, MANTRA 
log10[BF] = 6.18) that overlaps an intron in BAALC and that is approximately 32 kb 
upstream of FZD6. 
Loop diuretics with blood HDL cholesterol and LDL cholesterol 
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Analysis of the EA data identified no SNP that met the threshold for genome-wide 
significance or suggestive association for SNP-loop diuretic interactions on HDL or LDL 
cholesterol concentrations. Three SNPs (two loci) showed suggestive association in 
analyses of AA data on HDL concentrations (Supplementary Figure 7). Trans-ancestry 
analyses newly identified two SNPs in two loci with suggestive interaction associations 
on HDL, including a SNP on chromosome 11 in TEAD1 (rs7924536, P = 5.79•10-7, 
MANTRA log10[BF] = 5.22). 
For LDL analyses in AA (Supplementary Figure 8), one SNP on chromosome 6 
approximately 35 kb 5’ of PHIP reached genome-wide significance (rs12208017, P = 
3.73•10-8, βGD = 0.81 ± 0.02); this SNP is in an expression quantitative trait locus 
(eQTL) for both PHIP and the adjacent gene, IRAK1BP1. An additional SNP with a 
suggestive association (rs1312663, P = 4.06•10-7) is located approximately 100 kb 
upstream of SLC24A4 .  
Thiazide diuretics with blood TG, HDL cholesterol and LDL cholesterol 
For analyses of SNP-thiazide diuretic interactions in EA and AA, no loci reached 
genome-wide significance for TG, HDL or LDL (Supplementary Figures 9-11). In EA, 
suggestive association was noted with one SNP in MYO16 (rs1926511, P = 1.05•10-7) 
for TG and three SNPs (in two loci) for LDL. In AA, 8 SNPs in two loci yielded 
suggestive associations with HDL including a seven-SNP locus on chromosome 14 in 
TRIP11 (most significant rs10083510, P = 3.20•10-7). SNPs in this locus are eQTLs for 
FBLN5. 
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In trans-ancestry analyses, a single intronic SNP on chromosome 20 in MACROD2 
(rs6043629, P = 1.12•10-8, βGD = 0.09 ± 0.02, MANTRA log10[BF] = 6.42) reached 
genome-wide significance for a thiazide diuretic interaction association on HDL; the 
strength of the association in EA (P = 1.25•10-5) and AA (P = 1.82•10-4) cohorts 
analyzed separately were much lower. Likewise, with analysis of SNP-thiazide 
interactions on LDL, two SNPs on chromosome 17 in KIAA0753 reached genome-wide 
significance based on the MANTRA analysis (most significant rs2304976, MANTRA 
log10[BF] = 5.34) although neither SNP approached significance in separate EA and AA 
analyses.  
Discussion 
A genome-wide meta-analyses with 39 710 European-ancestry (EA) individuals and 
9 925 African-ancestry (AA) individuals was performed to identify genetic variants that 
modify the effect of loop or thiazide diuretic use on blood lipid concentrations. Separate 
analyses of EA and AA data identified genome-wide significant variants in 3 loci with 
loop diuretic-SNP interaction on TG concentrations; trans-ancestry analysis 
strengthened evidence of association at two additional loci. The most significant 
associations were observed between loop diuretics and TG concentrations; intronic 
SNPs clustered in COL11A1 (collagen, type XI, alpha 1) on chromosome 1 were 
significantly associated with TG concentrations in EA. COL11A1 produces a 
structural/adhesion protein secreted by primary rat adipocytes.37 The expression of this 
gene is up-regulated during human adipogenesis38 which suggests a role in the 
modulation of lipid traits. Although it remains unclear how diuretics modulate the effect 
of COL11A1 variants on lipid traits, a COL11A1 mutation has been associated with 
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nephrogenic diabetes insipidus,39 which is characterized by an inability of the kidney to 
concentrate urine, thus providing a possible mechanistic link between COL11A1, 
diuretics, and lipids.  
Trans-ancestry analysis combining European and African results provided evidence of 
association at intronic SNPs clustered in KIAA1217 (an uncharacterized long coding 
DNA) which are just 5’ to an intronic microRNA (MIR603) on chromosome 10. 
KIAA1217 variants have been associated with obesity.40 MIR603 has been associated 
with benign and malignant tumors.41-44 Of potential interest, SNPs in both KIAA1217 
and COL11A1 have been associated with lumbar disk herniation which, in turn, has 
been associated with blood lipid concentrations45 and cardiovascular risk traits and 
disease.46  
Loci with genome-wide significant associations found in intragenic regions may impact 
the transcription of genes tens or hundreds of kilobases away from their target genes.47 
The cluster of SNPs on chromosome 20 reaching genome-wide significance for TG in 
AA lies between two genes. FERMT1 (fermitin family member 1) is a membrane-
associated protein that links intracellular structural proteins to the extracellular matrix. 
While mutations in this gene have been implicated in a heritable skin disorder,48 
connections to cardiovascular traits are sparse. Perhaps more relevant is this locus’ 
proximity to BMP2 (bone morphogenetic protein 2), the expression of which is regulated 
by angiotensin II,49 a key regulator of blood pressure and fluid/electrolyte balance. 
Furthermore, BMP2, a member of the transforming growth factor (TGF)-β superfamily of 
cytokines, is expressed in endothelial cells, and has been shown to stimulate adjacent 
smooth muscle and endothelial cells to proliferate, differentiate, and deposit extra-
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cellular matrix, thus affecting blood pressure and contributing to atherosclerosis by 
processes that also includes Wnt signaling.50 BMP2 also participates in the 
differentiation of mesenchymal stem cells to mature adipocytes,51 thus potentially 
affecting blood lipid concentrations. 
A cluster of SNPs spanning the 3’ end and intragenic region adjacent to BAALC and 5’ 
of FZD6 was nominally associated with TG response to loop diuretic therapy in both 
races; however, trans-ancestry meta-analysis by METAL and MANTRA strengthened 
the association. There is little evidence to link BAALC (brain and acute leukemia, 
cytoplasmic) with TG concentrations. However, both FZD6 (frizzled class receptor 6), 
which is approximately 32 kb downstream from this locus on chromosome 8, and DKK1 
(dickkopf WNT signaling pathway inhibitor 1) on chromosome 10 are negative regulars 
of the β-catenin/Wnt signaling cascade.52,53 Expression of DKK1 has been noted in 
atherosclerotic plaques54 and shown to induce PPARγ expression (a key regulator of 
adipogenesis),55 further drawing a link between DKK1 and blood lipid concentrations. 
Both FZD6 and DKK1 have also been associated with renal development,56,57 
glomerular damage, and proteinuria.58,59 The DKK1 locus may be of additional interest 
since rs1441122 shows moderate evidence of altering the binding motif for the 
transcription factor TRIM28 (also known as KAP1) in a human embryonic kidney cell 
line; TRIM28 expression has been shown to play a role in signaling pathways 
responsible for renal fibrosis,60 a key risk factor for cardiovascular disease traits 
including hypertension and elevated TG concentrations.61 Finally, not only does β-
catenin/Wnt alter the expression of genes which regulate renal sodium, chloride and 
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potassium handling,62 but the pathway is also inhibited by the loop diuretic ethacrynic 
acid.63  
Evidence of SNP-loop diuretic interactions on HDL and LDL cholesterol was relatively 
sparse. Although no SNP met thresholds for genome-wide or suggestive association in 
EA, analyses in AA did identify potentially interesting associations. Loop diuretic-HDL 
analyses in AA identified a genome-wide significant association for a SNP adjacent to 
ROBO2 (roundabout, axon guidance receptor, homolog 2).The ROBO2 receptor and its 
binding partner SLIT1 play a role in mediating axonal growth in the brain.64 ROBO2 also 
plays a role in kidney development and function.65,66 Trans-ancestry analyses identified 
SNPs in TEAD1 (TEA domain family member 1 [SV40 transcriptional enhancer factor]) 
as significantly associated with HDL concentrations. This transcription factor is another 
β-catenin/Wnt pathway member67 that has been shown to modulate adipocyte 
differentiation and proliferation68 and play a role in regulating insulin sensitivity via 
skeletal muscle fiber type switching.69,70  
 
In the analyses of AA data with LDL, a SNP reaching genome-wide significance 
adjacent to PHIP (pleckstrin homology domain interacting protein) is within 270 kb of 
another SNP (rs16890334) previously identified as having a genome-wide significant 
association with blood pressure response to a high-sodium diet intervention in Han 
Chinese.71 Another SNP approximately 100 kb upstream of SLC24A4 (solute carrier 
family 24 [sodium/potassium/calcium exchanger], member 4) may have relevant links to 
loop diuretic use. SNPs in SLC24A4 have shown genome-wide significant association 
with systolic blood pressure in AA individuals72 as well as with LDL and lipoprotein 
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particle concentrations following fenofibrate therapy in the Genetics of Lipid Lowering 
Drugs and Diet Network (GOLDN) study.73  
A few loci from analyses of thiazide and thiazide-like diuretics with lipid traits were 
notable despite not reaching genome-wide significance. SNPs in MYO16 (myosin XVI) 
have been previously associated with nephrotic syndrome in humans and mice;74-77 
nephrotic syndrome is a significant risk factor of lipid abnormalities.61 SNPs in TRIP11 
(thyroid hormone receptor interactor 11), which are eQTLs for FBLN5 (fibulin 5), are 
also of interest given prior suggestive association of FBLN5 with HDL mean particle 
size.78 Trans-ancestry analyses identified a MACROD2 (MACRO domain containing 2) 
with genome-wide significance for a diuretic interaction effect on HDL. This gene was 
found to have a significant association with coronary artery disease and hypertension 
using a two-marker testing approach in a reanalysis of data from the Wellcome Trust 
Case Control Consortium,79 and a suggestive association with brain infarcts in another 
meta-analysis;80 however, the role of this gene in determining cardiovascular traits 
remain uncertain. 
Limitations 
Although this study identified interesting loop diuretic-SNP interactions as modulators of 
TG concentrations, there were limitations in this study. First, the study design assumed 
therapeutic class effects although individual drugs may have different effects on 
lipids.7,81,82 Information regarding the dosage, duration, or adequacy of diuretic therapy 
may have also affected the traits but were not available in most studies. Second, 
because potassium-sparing diuretics were frequently co-administered with thiazide and 
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thiazide-like diuretics, it was not feasible to pursue the sole contributions of potassium-
sparing diuretics which were therefore not considered in this study. Third, the potential 
contribution of co-morbidities such as diabetes and renal dysfunction on lipid traits was 
not considered, although diuretics have been shown to be less effective at controlling 
blood pressure and cause greater increases in LDL and TG concentrations in 
diabetics.7 Fourth, the relatively smaller number of AA subjects exposed to diuretics 
may have reduced the power to detect significant association or increased the risk for 
spurious findings in this ancestry group. Finally, given the number of tests performed 
and the relatively small effect size for the interaction, this effort should be construed as 
a discovery analysis that warrants replication. 
Conclusions 
This genome-wide meta-analysis accounting for SNP-diuretic interactions on blood lipid 
concentrations used data from 39 710 European-ancestry individuals and 9 925 African-
ancestry individuals. The results of the present study suggest stronger interaction 
effects for loop versus thiazide diuretics identifying several genome-wide significant loci 
of small effect sizes. The results of this medication interaction study may help identify 
biologic pathways that contribute to adverse metabolic side effects from diuretic 
therapy. These findings may also explain, at least in part, some of the residual CVD risk 
following reduction of blood pressure in patients treated with anti-hypertensive 
medications. 
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Figure Legends 
 
Figure 1: Manhattan plots for analysis of loop diuretic-SNP interaction on triglyceride 
concentrations. The ancestry-sepcific meta-analysis used 11 cohorts of European 
ancestry (upper-left panel) and 6 cohorts of African ancestry (lower-left panel). Trans-
ancestry meta-analysis used fixed-effect weighted Z-statistics with METAL (upper-right 
panel) and a Bayesian framework with MANTRA (lower-right panel). The -log10(P) from 
METAL or log10(Bayes Factor) from MANTRA was plotted at the chromosomal location 
of each variant. Manhattan plots for the remaining lipid-diuretic pairs are shown in 
Supplementary Figures 7-11. 
Figure 2: Regional plots of significant SNP-loop diuretic interaction effects on 
triglyceride concentrations on chromosome 1 in European ancestry (top), chromosome 
20 in African ancestry (middle), and chromosome 10 in trans-ancestry analyses of 
European and African ancestries (bottom). Plots were created using LocusZoom 
software (http://csg.sph.umich.edu/locuszoom/). Linkage disequilibrium (LD, r2) was 
based on hg19/1000 Genomes Nov 2014 EUR for EA and AFR hg19/1000 Genomes 
Nov 2014 for AA. Because no LD information was available for trans-ancestry results 
combining EA and AA results, the bottom plot does not show LD. 
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Tables 
Table 1. Baseline characteristics of 21 participating cohorts of 
European and African ancestry. 17 cohorts were used for loop 
diuretic analysis.  
Ancestry Study N 
Loop 
Exposed 
Subjects 
Thiazide 
Exposed 
Subjects 
European 
AGES 1,677 153 466 
ARIC 8,963 387 1,471 
CHS 3,174 181 764 
FHS 7,680 177 540 
Health ABC 1,828 130 329 
HVH1 470 51 184 
HVH2 206 21 83 
HyperGEN 1,187 44 196 
MESA 2,359 NA 563 
PROSPER 4,592 618 1,402 
RS1 3,421 269 405 
RS2 2,096 86 147 
WHI CT GARNET Baseline 1,198 NA 142 
WHI CT GARNET Core 859 NA 186 
African 
ARIC 2,295 156 1,072 
CHS 709 95 235 
HyperGEN 1,110 86 278 
JHS 1,500 91 381 
WHI CT SHARe Baseline 3,486 150 752 
WHI CT SHARe Core 825 NA 362 
WHI OS SHARe Baseline 3,422 206 843 
Abbreviations: AGES, Age, Gene/Environment Susceptibility-
Reykjavik Study; ARIC, Atherosclerosis Risk in Communities study; 
CHS, Cardiovascular Health Study; CT, Clinical Trial, FHS, 
Framingham Heart Study; GARNET, Genomics and Randomized 
Trial Network; Health ABC, Health Aging, Body and Composition; 
HyperGEN, Hypertension Genetic Epidemiology Network; HVH, 
Heart and Vascular Health; JHS, Jackson Heart Study; MESA, Multi-
Ethnic Study of Atherosclerosis; OS, Observational Study; 
PROSPER, PROspective Study of Pravastatin in the Elderly at Risk; 
RS, Rotterdam Study; SHARe, SNP Health Association Resource; 
WHI, Women’s Health Initiative. 
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Table 2. Genome-wide significant SNPs from European-Ancestry, African-Ancestry, Transethnic, and MANTRA analyses for loop 
diuretic-SNP interactions on triglyceride concentrations. 
Marker Chr Position Alleles 
European Ancestry 
 
African Ancestry 
 
Transethnic 
 
MANTRA 
log10(BF) 
Neighboring Genes 
Freq P 
 
Freq P 
 
Freq P   
rs1463034 1 103,227,805 t/c 0.92 1.31E-09 
 
0.59 4.40E-01 
 
0.83 1.78E-06 
 
6.50 
COL11A1 
rs1870958 1 103,229,744 t/g 0.92 1.76E-09 
 
0.59 5.00E-01 
 
0.82 3.16E-06 
 
6.68 
rs2786125 1 103,235,061 a/g 0.06 1.24E-08 
 
0.31 4.37E-01 
 
0.14 1.65E-05 
 
6.64 
rs2622870 1 103,236,564 t/g 0.94 1.27E-08 
 
0.69 3.40E-01 
 
0.87 1.61E-05 
 
7.11 
rs2622874 1 103,239,505 a/c 0.06 1.23E-08 
 
0.31 3.26E-01 
 
0.13 1.74E-05 
 
6.80 
rs7544444 1 103,293,408 t/c 0.97 3.66E-06 
 
0.86 6.27E-02 
 
0.93 4.67E-03 
 
5.26 
rs7607797 2 117,944,672 t/c 0.97 3.60E-08 
 
0.66 4.62E-01 
 
0.86 6.94E-05 
 
3.78 DDX18 
rs4554091 4 130,520,065 t/g 0.58 4.19E-01 
 
0.16 5.65E-08 
 
0.46 3.65E-02 
 
5.44 SCLT1 / LOC105377417 
rs11100093 4 158,213,492 a/t 0.15 3.67E-05 
 
0.19 1.70E-02 
 
0.16 2.32E-06 
 
5.53 PDGFC / GLRB / GRIA2 
rs7817074 8 104,300,634 t/g 0.05 6.72E-05 
 
0.04 2.39E-02 
 
0.05 6.31E-06 
 
5.58 
 BAALC / FZD6 
rs7841861 8 104,329,002 t/c 0.06 4.38E-05 
 
0.13 2.46E-02 
 
0.08 3.92E-06 
 
6.10 
rs7002454 8 104,347,955 t/c 0.95 7.71E-05 
 
0.87 3.58E-02 
 
0.93 9.78E-06 
 
6.01 
rs6985929 8 104,348,009 a/g 0.95 7.78E-05 
 
0.87 3.29E-02 
 
0.93 9.07E-06 
 
6.18 
rs7899031 10 24,560,897 t/c 0.97 7.52E-07 
 
0.86 2.34E-02 
 
0.93 1.27E-07 
 
5.22 KIAA1217 / MIR603 / 
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rs10508671 10 24,574,062 t/c 0.03 9.43E-07 
 
0.25 2.12E-03 
 
0.11 1.08E-08 
 
6.24 
ARHGAP21 
rs10508672 10 24,574,441 a/g 0.03 9.52E-07 
 
0.24 2.32E-03 
 
0.11 1.19E-08 
 
6.21 
rs7071454 10 24,575,819 t/c 0.03 9.63E-07 
 
0.25 1.18E-02 
 
0.11 8.28E-08 
 
5.52 
rs11013993 10 24,577,638 t/c 0.03 1.22E-06 
 
0.25 1.26E-02 
 
0.11 1.11E-07 
 
5.39 
rs749140 10 130,259,880 t/c 0.96 5.52E-06 
 
0.95 3.55E-01 
 
0.96 1.94E-05 
 
5.22 
PTPRE / MKI67 / 
LINC01163 
rs11016373 10 130,286,692 t/c 0.04 5.47E-07 
 
0.08 6.91E-01 
 
0.05 1.32E-05 
 
5.24 
rs16921999 11 94,872,381 a/c 0.03 1.99E-04 
 
0.04 1.11E-03 
 
0.03 1.23E-06 
 
5.10 
ENDOD1 / SESN3 / 
FAM76B / CEP57 / MTMR2 
rs3852940 20 6,165,600 a/g 0.79 7.10E-01 
 
0.70 1.18E-08 
 
0.77 9.80E-03 
 
6.07 
CRLS1 / LRRN4 / FERMT1 
/ CASC20 / BMP2 
rs6054016 20 6,174,368 t/c 0.06 6.18E-01 
 
0.19 4.06E-10 
 
0.10 2.05E-03 
 
6.22 
rs6054018 20 6,175,236 t/g 0.94 6.24E-01 
 
0.80 1.70E-10 
 
0.90 1.75E-03 
 
8.26 
rs8120588 20 6,178,849 t/c 0.94 6.36E-01 
 
0.81 3.75E-10 
 
0.90 1.79E-03 
 
8.09 
rs7348828 20 6,182,498 a/g 0.94 6.50E-01 
 
0.81 3.56E-10 
 
0.90 1.67E-03 
 
7.99 
rs8122198 20 6,186,686 t/c 0.94 9.11E-01 
 
0.85 9.53E-09 
 
0.91 2.36E-03 
 
6.44 
rs6054037 20 6,187,877 c/g 0.94 8.82E-01 
 
0.85 9.94E-09 
 
0.91 2.61E-03 
 
6.22 
rs6038400 20 6,188,201 a/c 0.06 8.79E-01 
 
0.15 1.03E-08 
 
0.09 2.66E-03 
 
6.45 
rs3852942 20 6,192,559 a/g 0.06 8.84E-01 
 
0.17 3.36E-08 
 
0.10 3.31E-03 
 
5.15 
rs7262233 20 51,534,628 a/g 0.06 9.45E-06 
 
0.09 4.75E-01 
 
0.07 4.46E-05 
 
5.43 TSHZ2 / ZNF217  
Abbreviations: Chr, chromosome, Freq, frequency of allele 1. Bolded genes include intragenic SNPs. 
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Supplementary Table 1. Genotyping, imputation, and statistical analysis for participating cohorts. 
Ancestry Study Genotyping Platform Genotype Inclusion Criteria 
Imputation 
Software 
Association 
Test 
European 
AGES Illumina Hu370CNV 
Call rates >97%, P 
HWE >1e-6 
MACH ProbABEL 
ARIC Affymetrix 6.0 
Call rates >90%, P 
HWE >1e-5 
MACH boss (R) 
CHS Illumina 370CNV 
Call rates >97%, P 
HWE >1e-5 
BIMBAM boss (R) 
FHS Affymetrix 500K + 50 MIP 
Call rates >97%, P 
HWE >1e-6 
MACH R 
Health ABC Illumina 1M 
Call rates >97%, P 
HWE >1e-6 
MACH ProbABEL 
HyperGEN Affymetrix GeneChip SNP Array 5.0 
Call rates >95%, P 
HWE >1e-6 
MACH ProbABEL 
HVH1 Illumina 370CNV 
Call rates >97%, P 
HWE >1e-5 
BIMBAM R 
HVH2 Illumina Omni Express 
Call rates >97%, P 
HWE >1e-5 
MACH R 
MESA Affymetrix 6.0 
Call rates >90%, P 
HWE >1e-4 
IMPUTE ProbABEL 
PROSPER Illumina 660K 
Call rates >97.5%, P 
HWE >1e-6 
MACH ProbABEL 
RS1 Illumina 550k 
Call rates >98%, P 
HWE >1e-6 
MACH ProbABEL 
RS2 Illumina 550K Duo, 610KQuad 
Call rates >95%, P 
HWE >1e-6 
MACH ProbABEL 
WHI CT GARNET  
Controls Baseline 
Illumina Human Omni1-Quad v1-0 B 
Call rates >98%, P 
HWE >1e-4 
BEAGLE boss (R) 
WHI CT GARNET Core Illumina Human Omni1-Quad v1-0 B 
Call rates >98%, P 
HWE >1e-4 
BEAGLE boss (R) 
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Ancestry Study Genotyping Platform Genotype Inclusion Criteria Imputation Software Association Test 
African 
ARIC Affymetrix GeneChip SNP Array 6.0 
Call rates >90%, 
MAF ≥1% MACH boss (R) 
CHS Illumina Human Omni1-Quad_v1 BeadChip 
Call rates >97%, P 
HWE >1e-5 
BEAGLE 
3.2.1 
boss (R) 
HyperGEN Affymetrix GeneChip SNP Array 6.0 
Call rates >95%, P 
HWE >1e-6 
MACH ProbABEL 
JHS Affymetrix GeneChip SNP Array 6.0 Call rates >90%  MACH boss (R) 
WHI CT SHARe Baseline Affymetrix GeneChip SNP Array 6.0 
Call rates >95%, P 
HWE >1e-6 
MACH boss (R) 
WHI CT SHARe Core Affymetrix GeneChip SNP Array 6.0 
Call rates >95%, P 
HWE >1e-6 
MACH boss (R) 
WHI OS SHARe Baseline Affymetrix GeneChip SNP Array 6.0 
Call rates >95%, P 
HWE >1e-6 
MACH boss (R) 
Abbreviations: AGES, Age, Gene/Environment Susceptibility-Reykjavik Study; ARIC, Atherosclerosis Risk in Communities study; CHS, 
Cardiovascular Health Study; CT, Clinical Trial, FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into 
Effects of Treatment; Health ABC, Health Aging, Body and Composition; HyperGEN, Hypertension Genetic Epidemiology Network; HVH, Heart and 
Vascular Health; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study of Atherosclerosis; OS, Observational Study; PROSPER, PROspective 
Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, SNP Health Association Resource; WHI, Women’s Health Initiative. 
 
  
MANTRA
Freq P HetPVal Freq P HetPVal Freq P HetPVal log 10 BF
rs12563198 1 59,718,894 a/g 0.96 5.48E-07 5.42E-01 0.91 9.85E-01 7.15E-01 0.95 2.15E-05 1.02E-02 3.90
rs11808336 1 59,736,902 t/c 0.03 3.75E-07 4.46E-01 0.06 9.17E-01 9.73E-01 0.04 1.54E-05 9.68E-03 4.35
rs17119531 1 59,740,182 a/g 0.97 3.82E-07 4.45E-01 0.94 9.01E-01 9.62E-01 0.96 1.29E-05 1.20E-02 4.62
rs1463034 1 103,227,805 t/c 0.92 1.31E-09 3.25E-01 0.59 4.40E-01 7.68E-01 0.83 1.78E-06 1.92E-04 6.50
rs1870958 1 103,229,744 t/g 0.92 1.76E-09 2.35E-01 0.59 5.00E-01 8.23E-01 0.82 3.16E-06 1.54E-04 6.68
rs2786125 1 103,235,061 a/g 0.06 1.24E-08 1.21E-01 0.31 4.37E-01 8.66E-01 0.14 1.65E-05 1.93E-04 6.64
rs2622870 1 103,236,564 t/g 0.94 1.27E-08 1.22E-01 0.69 3.40E-01 8.28E-01 0.87 1.61E-05 1.72E-04 7.11
rs2622874 1 103,239,505 a/c 0.06 1.23E-08 1.21E-01 0.31 3.26E-01 8.02E-01 0.13 1.74E-05 1.51E-04 6.80
rs7544444 1 103,293,408 t/c 0.97 3.66E-06 1.82E-01 0.86 6.27E-02 9.06E-01 0.93 4.67E-03 4.99E-05 5.26
rs7607797 2 117,944,672 t/c 0.97 3.60E-08 1.18E-01 0.66 4.62E-01 9.62E-01 0.86 6.94E-05 1.38E-04 3.78 DDX18
rs4554091 4 130,520,065 t/g 0.58 4.19E-01 6.18E-01 0.16 5.65E-08 6.03E-01 0.46 3.65E-02 5.23E-07 5.44
rs7691747 4 130,528,914 a/g 0.46 6.01E-01 6.33E-01 0.83 1.58E-07 9.96E-01 0.56 2.22E-02 2.74E-06 3.43
rs11100093 4 158,213,492 a/t 0.15 3.67E-05 3.88E-01 0.19 1.70E-02 3.74E-01 0.16 2.32E-06 9.31E-01 5.53 PDGFC / GLRB / GRIA2
rs7817074 8 104,300,634 t/g 0.05 6.72E-05 6.74E-03 0.04 2.39E-02 6.90E-01 0.05 6.31E-06 6.38E-01 5.58
rs7841861 8 104,329,002 t/c 0.06 4.38E-05 1.36E-02 0.13 2.46E-02 5.55E-01 0.08 3.92E-06 8.13E-01 6.10
rs7002454 8 104,347,955 t/c 0.95 7.71E-05 6.10E-03 0.87 3.58E-02 5.20E-01 0.93 9.78E-06 7.29E-01 6.01
rs6985929 8 104,348,009 a/g 0.95 7.78E-05 6.03E-03 0.87 3.29E-02 5.35E-01 0.93 9.07E-06 7.51E-01 6.18
rs12351434 9 103,449,707 a/g 0.05 1.84E-06 7.61E-01 0.16 7.51E-02 7.78E-01 0.08 7.95E-07 2.96E-01 4.40 GRIN3A
rs7077598 10 24,558,186 a/g 0.03 7.48E-07 2.55E-02 0.18 3.83E-02 8.29E-01 0.08 2.37E-07 2.12E-01 4.87
rs7899031 10 24,560,897 t/c 0.97 7.52E-07 2.56E-02 0.86 2.34E-02 9.66E-01 0.93 1.27E-07 2.78E-01 5.22
rs10508671 10 24,574,062 t/c 0.03 9.43E-07 2.67E-02 0.25 2.12E-03 6.38E-01 0.11 1.08E-08 6.69E-01 6.24
rs10508672 10 24,574,441 a/g 0.03 9.52E-07 2.69E-02 0.24 2.32E-03 6.82E-01 0.11 1.19E-08 6.57E-01 6.21
rs7071454 10 24,575,819 t/c 0.03 9.63E-07 2.69E-02 0.25 1.18E-02 4.19E-01 0.11 8.28E-08 3.05E-01 5.52
rs12251962 10 24,576,990 a/g 0.03 9.76E-07 2.69E-02 0.11 7.79E-02 5.69E-01 0.06 6.59E-07 1.71E-01 4.88
rs11013993 10 24,577,638 t/c 0.03 1.22E-06 2.51E-02 0.25 1.26E-02 4.17E-01 0.11 1.11E-07 3.04E-01 5.39
rs1612115 10 53,893,261 t/c 0.97 2.31E-07 4.79E-01 0.84 4.41E-01 9.01E-01 0.93 1.31E-04 4.65E-04 1.92
rs1441118 10 53,910,163 t/c 0.97 8.16E-07 2.05E-01 0.85 3.15E-01 4.36E-01 0.92 1.48E-03 1.21E-04 2.26
rs10762762 10 53,923,822 a/g 0.03 1.12E-07 3.52E-01 0.13 3.19E-01 2.92E-01 0.07 2.71E-04 8.82E-05 2.25
rs1620449 10 53,924,468 t/c 0.97 3.27E-07 2.16E-01 0.85 4.73E-01 3.70E-01 0.93 3.14E-04 2.88E-04 2.36
rs1660756 10 53,929,701 t/c 0.03 6.66E-07 1.62E-01
rs1441125 10 53,931,168 t/c 0.97 6.84E-07 1.60E-01 0.85 4.65E-01 2.70E-01 0.93 4.47E-04 4.23E-04 2.25
rs1733732 10 53,932,187 t/c 0.97 9.49E-07 1.46E-01 0.85 3.48E-01 2.51E-01 0.92 9.14E-04 2.42E-04 2.19
rs1730463 10 53,933,172 a/g 0.03 9.19E-07 1.43E-01 0.15 6.66E-01 3.26E-01 0.07 2.05E-04 1.51E-03 2.22
rs1730462 10 53,933,391 a/g 0.03 9.22E-07 1.43E-01 0.15 2.73E-01 2.67E-01 0.07 1.26E-03 1.45E-04 2.24
rs1733735 10 53,936,820 t/c 0.97 9.39E-07 1.44E-01 0.85 3.33E-01 2.57E-01 0.92 9.72E-04 2.18E-04 2.14
rs1441122 10 53,938,711 a/c 0.03 9.33E-07 1.44E-01 0.15 6.60E-01 3.25E-01 0.07 2.07E-04 1.52E-03 2.08
rs1733701 10 53,944,852 a/t 0.97 9.32E-07 1.44E-01 0.86 7.16E-01 3.82E-01 0.93 1.75E-04 1.85E-03 2.35
rs16930890 10 53,946,621 a/g 0.97 9.86E-07 1.41E-01 0.93 2.42E-01 3.20E-01 0.96 9.63E-05 1.87E-03 2.85
rs749140 10 130,259,880 t/c 0.96 5.52E-06 6.56E-02 0.95 3.55E-01 1.47E-01 0.96 1.94E-05 8.96E-02 5.22
rs11016373 10 130,286,692 t/c 0.04 5.47E-07 9.05E-02 0.08 6.91E-01 6.37E-01 0.05 1.32E-05 1.58E-02 5.24
rs16921999 11 94,872,381 a/c 0.03 1.99E-04 2.72E-01 0.04 1.11E-03 3.81E-01 0.03 1.23E-06 4.84E-01 5.10 ENDOD1 / SESN3 / FAM76B / CEP57 / MTMR2
Supplementary Table 2. Genome-wide significant and suggestive SNPs-diuretic interaction (P  < 10-6) on lipid traits.
FGGY
COL11A1
SCLT1 / LOC105377417
KIAA1217 / MIR603 / ARHGAP21
PRKG1 / DKK1 / LINC01468 / LOC105378305
PTPRE / MKI67 / LINC01163
BAALC / FZD6
Trans Ancestry
Neighboring Genes
Loop Diuretic - Triglyceride
Marker Chr Position Alleles
European Ancestry African Ancestry
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Freq P HetPVal(t) Freq P HetPVal Freq P HetPVal log 10 BF
rs2790503 14 51,378,963 a/c 0.96 1.74E-07 6.21E-01 0.72 6.58E-01 4.85E-01 0.89 4.43E-06 1.47E-02 3.90 FRMD6 / FRMD6-AS1 / GNG2 / LOC102723604
rs2278458 15 20,551,298 a/g 0.04 4.25E-07 4.67E-01 0.30 4.63E-01 7.63E-01 0.11 3.37E-06 4.39E-02 3.64 NIPA1 / NIPA2 / CYFIP1 / TUBGCP5
rs11863116 16 83,876,060 a/g 0.84 2.84E-07 6.67E-01 0.72 3.40E-01 6.81E-01 0.82 9.89E-06 7.09E-03 3.84 LINC00311 / GSE1 / GINS2 / FAM92B 
rs3852940 20 6,165,600 a/g 0.79 7.10E-01 9.80E-01 0.70 1.18E-08 8.95E-01 0.77 9.80E-03 4.76E-07 6.07
rs6054016 20 6,174,368 t/c 0.06 6.18E-01 1.56E-01 0.19 4.06E-10 2.76E-01 0.10 2.05E-03 6.99E-08 6.22
rs6054018 20 6,175,236 t/g 0.94 6.24E-01 1.54E-01 0.80 1.70E-10 3.14E-01 0.90 1.75E-03 3.46E-08 8.26
rs8120588 20 6,178,849 t/c 0.94 6.36E-01 1.49E-01 0.81 3.75E-10 2.77E-01 0.90 1.79E-03 7.44E-08 8.09
rs7348828 20 6,182,498 a/g 0.94 6.50E-01 1.29E-01 0.81 3.56E-10 2.78E-01 0.90 1.67E-03 7.65E-08 7.99
rs8122198 20 6,186,686 t/c 0.94 9.11E-01 7.73E-02 0.85 9.53E-09 3.92E-01 0.91 2.36E-03 1.57E-06 6.44
rs6054037 20 6,187,877 c/g 0.94 8.82E-01 7.25E-02 0.85 9.94E-09 3.90E-01 0.91 2.61E-03 1.48E-06 6.22
rs6038400 20 6,188,201 a/c 0.06 8.79E-01 7.14E-02 0.15 1.03E-08 3.90E-01 0.09 2.66E-03 1.50E-06 6.45
rs3885310 20 6,191,754 t/c 0.06 8.78E-01 7.39E-02 0.17 1.23E-07 2.89E-01 0.09 7.43E-03 6.64E-06 3.91
rs3852942 20 6,192,559 a/g 0.06 8.84E-01 7.36E-02 0.17 3.36E-08 4.18E-01 0.10 3.31E-03 3.94E-06 5.15
rs7508797 20 24,167,384 a/t 0.03 2.10E-01 1.97E-01 0.04 2.50E-07 6.33E-02 0.03 5.29E-04 7.73E-05 4.47 LINC01721
rs7262233 20 51,534,628 a/g 0.06 9.45E-06 2.48E-03 0.09 4.75E-01 5.95E-01 0.07 4.46E-05 7.77E-02 5.43
TSHZ2 / LOC101927770 / ZNF217 / 
LOC105372672 
rs12627019 21 22,811,777 t/c 0.06 8.33E-07 6.37E-02 LINC01687 / LINC00308
rs17130785 1 68,928,375 t/c 0.93 7.67E-05 3.41E-01 0.91 5.32E-03 3.71E-01 0.92 1.35E-06 8.07E-01 5.06 DEPDC1 / DEPDC1-AS1
rs2139476 2 34,534,998 a/c 0.20 9.14E-02 3.47E-01 0.06 9.63E-07 1.08E-01 0.19 1.57E-03 4.03E-05 2.99
rs2887973 2 34,541,414 a/c 0.80 4.90E-02 3.11E-01 0.94 7.49E-07 9.33E-02 0.81 6.19E-04 4.51E-05 2.71
rs11136986 8 6,060,930 t/c 0.94 1.31E-04 2.98E-01 0.85 1.93E-03 8.96E-01 0.92 9.71E-07 6.15E-01 4.59 LOC100287015 / MCPH1 / ANGPT2
rs7924536 11 12,874,326 t/c 0.98 1.53E-05 2.83E-01 0.77 1.06E-02 2.61E-01 0.90 5.79E-07 6.16E-01 5.22 TEAD1 / LINC00958
rs2422862 20 3,147,703 a/g 0.86 7.33E-01 1.99E-01 0.96 2.83E-07 1.61E-05 0.87 1.62E-02 5.38E-06 6.28 DDRGK1 / ITPA / SLC4A11
rs12208017 6 79,880,090 t/g 0.78 4.16E-01 2.16E-01 0.95 3.73E-08 4.92E-01 0.80 2.69E-01 4.99E-08 2.03 IRAK1BP1/ PHIP / HMGN3
rs1312663 14 91,758,433 a/g 0.10 5.42E-01 2.55E-01 0.04 4.06E-07 9.08E-02 0.09 1.47E-01 9.96E-07 0.96 TRIP11 / ATXN3 / NDUFB1 / CPSF2 / SLC24A4
rs4653061 1 34,844,885 a/g 0.48 4.16E-01 9.14E-01 0.19 6.15E-07 8.41E-01 0.38 2.16E-02 6.83E-06 4.33 GJB5 / GJB4 / GJB3 / GJA4 / SMIM12
rs1567793 6 67,180,515 t/c 0.63 7.60E-07 1.18E-01 0.62 5.76E-01 4.19E-01 0.63 2.82E-04 8.04E-04 2.89 EYS
rs1926511 13 108,153,937 t/c 0.27 1.05E-07 3.27E-01 0.18 2.76E-01 2.42E-01 0.24 4.17E-04 4.58E-05 3.71 MYO16
rs510438 18 55,084,025 a/c 0.19 6.45E-07 8.09E-01 0.09 6.05E-02 7.68E-01 0.16 9.84E-04 3.58E-05 4.54 GRP / RAX
Loop Diuretic - Triglyceride - continued
Alleles
European Ancestry African Ancestry Trans Ancestry
Neighboring Genes
Thiazide Diuretic - Triglyceride
CRLS1 / LRRN4 / FERMT1 / CASC20 / BMP2
Loop Diuretic - LDL
Loop Diuretic - HDL
LINC01318 / LINC01317 / LINC01320
Supplementary Table 2. Genome-wide significant and suggestive SNPs-diuretic interaction (P  < 10-6) on lipid traits – Continued.
Marker Chr Position
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rs1971692 9 124,904,313 t/g 0.86 1.29E-04 2.62E-01 0.54 1.19E-03 3.52E-01 0.73 5.87E-07 9.43E-01 4.23 GPR21 / RABGAP1 / MIR600 / STRBP
rs10507678 13 62,067,267 t/c 0.08 5.47E-01 8.49E-01 0.17 3.58E-07 5.30E-02 0.11 8.93E-04 9.71E-05 3.40
PCDH20 / LOC101926951 / LINC00358 / 
LINC01075
rs7154514 14 91,496,952 a/t 0.45 5.60E-01 9.42E-01 0.68 8.03E-07 8.77E-01 0.53 1.44E-02 1.56E-05 4.02
rs2295162 14 91,508,500 a/g 0.53 8.51E-01 9.60E-01 0.31 5.99E-07 8.66E-01 0.45 5.51E-03 3.34E-05 3.80
rs2295166 14 91,523,099 t/g 0.53 9.38E-01 8.01E-01 0.31 5.96E-07 8.59E-01 0.45 4.15E-03 4.42E-05 3.48
rs10083510 14 91,532,250 t/c 0.53 6.75E-01 9.59E-01 0.34 3.20E-07 9.99E-01 0.46 8.19E-03 1.13E-05 3.41
rs10083447 14 91,534,180 a/g 0.47 6.96E-01 9.60E-01 0.69 5.75E-07 8.61E-01 0.55 8.31E-03 2.05E-05 3.13
rs4904830 14 91,536,833 t/c 0.53 7.97E-01 9.14E-01 0.31 6.14E-07 8.60E-01 0.45 5.35E-03 3.47E-05 3.41
rs4575474 14 91,539,034 c/g 0.53 9.55E-01 7.56E-01 0.31 8.77E-07 8.61E-01 0.46 4.22E-03 6.45E-05 3.67
rs6043629 20 15,920,298 c/g 0.74 1.25E-05 7.19E-01 0.62 1.82E-04 8.69E-01 0.70 1.12E-08 6.41E-01 6.42 MACROD2 / LOC613266
rs9983495 21 30,118,644 t/g 0.04 2.73E-04 5.45E-01 0.26 2.80E-04 8.66E-01 0.13 3.63E-07 5.37E-01 3.88 GRIK1
rs12199608 6 743,361 c/g 0.11 7.55E-05 2.29E-01 0.03 2.99E-04 4.00E-01 0.10 4.14E-07 7.76E-02 4.41 EXOC2 / LOC101927691 / LINC01622
rs10840923 12 17,974,726 a/g 0.46 9.58E-07 2.02E-01 0.60 6.19E-01 6.14E-01 0.51 2.07E-04 1.20E-03 2.82
rs10840928 12 18,010,451 a/g 0.52 3.67E-07 9.47E-02 0.62 9.15E-01 6.04E-01 0.56 7.28E-05 1.46E-03 2.35
rs2359740 14 75,093,572 c/g 0.07 2.17E-07 2.62E-01 0.02 3.36E-01 2.44E-01 0.06 5.81E-05 6.46E-04 2.72 BATF / LOC102724153 / FLVCR2
rs4796525 17 6,456,407 t/c 0.05 1.48E-03 4.78E-02 0.19 9.53E-05 3.32E-01 0.10 8.98E-07 2.75E-01 4.91
rs2304976 17 6,466,743 a/g 0.05 6.22E-04 5.29E-02 0.19 8.78E-05 3.35E-01 0.11 3.06E-07 3.48E-01 5.34
rs2240275 17 6,484,840 a/g 0.05 1.27E-03 3.94E-02 0.19 7.70E-05 3.46E-01 0.11 5.83E-07 3.05E-01 5.15
Supplementary Table 2. Genome-wide significant and suggestive SNPs-diuretic interaction (P  < 10-6) on lipid traits – Continued.
Marker Chr Position Alleles
European Ancestry African Ancestry Trans Ancestry
Neighboring Genes
Abbreviations: Chr, chromosome, Freq, frequency of allele 1; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. Bolded genes include intragenic SNPs.
RERGL / PIK3C2G
PITPNM3 / KIAA0753 / TXNDC17 / MED31 / 
SLC13A5
Thiazide Diuretic - HDL
FBLN5 / TRIP11/ ATXN3
Thiazide Diuretic - LDL
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Study Descriptions  
AGES (Age Gene/Environment Susceptibility Reykjavik Study): The Reykjavik Study cohort originally was 
composed of a random sample of 30 795 men and women born in 1907-1935 and living in Reykjavik in 1967.1 
A total of 19 381 attended, resulting in 71% recruitment rate. The study sample was divided into six groups by 
birth year and birth date within month. One group was designated for longitudinal follow-up and was examined 
in all stages. Another group was designated a control group and was not included in examinations until 1991. 
Other groups were invited to participate in specific stages of the study. Between 2002 and 2006, the AGES-
Reykjavik study re-examined 5 764 survivors of the original cohort who had participated before in the Reykjavik 
Study.  
ARIC (Atherosclerosis Risk in Communities): The ARIC study is an ongoing population-based cohort of 
15 792 predominantly Caucasian and African-American males and females aged 45-64 years at baseline and 
selected using probability sampling from four United States communities (Forsyth County NC, Jackson MS, 
suburban Minneapolis MN, and Washington County MD).2 Participants were recruited in 1987-1989 to examine 
cardiovascular and pulmonary disease, patterns of medical care, and disease variation over time. 
Standardized physical examinations and interviewer-administered questionnaires were conducted at baseline 
(1987-1989), and at three triennial follow-up examinations (1990-1998). 
CHS (Cardiovascular Health Study): CHS is a population-based cohort study of risk factors for CHD and 
stroke in adults ≥65 years conducted across four field centers.3 The original predominantly Caucasian cohort of 
5 201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists; subsequently, 
an additional predominantly African-American cohort of 687 persons was enrolled for a total sample of 5 888. 
DNA was extracted from blood samples drawn on all participants at their baseline examination in 1989-90. In 
2007-2008, genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping 
Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system on 3 980 CHS participants who were 
free of CVD at baseline, consented to genetic testing, and had DNA available for genotyping. Because the 
other cohorts were predominantly white, the African American participants were excluded from this analysis to 
reduce the possibility of confounding by population structure.  
FHS (Framingham Heart Study): The FHS is a prospective, community based cohort study that was initiated 
in 1948 and now spans 3 generations, including the original cohort, their offspring and spouses of the offspring 
(Offspring Cohort, enrollment- beginning in 1971), and children from the largest offspring families (Generation 
3 Cohort, enrollment beginning in 2000). Details regarding study recruitment and design have been reported 
previously.4,5 All study protocols were approved by the Institutional Review Board for Boston University Medical 
Center. All study participants provided informed written consent.   
Health ABC (Health, Aging, and Body Composition): The Health ABC Study is a NIA-sponsored cohort 
study of the factors that contribute to incident disability and the decline in function of healthier older persons, 
with a particular emphasis on changes in body composition in old age. Between 4/15/97 and 6/5/98 the Health 
ABC study has recruited 3 075 70-79 year old community-dwelling adults (41% African-American), who were 
initially free of mobility and activities of daily living disability. The key components of Health ABC include a 
baseline exam, annual follow-up clinical exams, and phone contacts every 6 months to identify major health 
events and document functional status between clinic visits. Provision has been made for banking of blood 
specimens and extracted DNA (Health ABC repository). 
HVH (Heart and Vascular Health Study): The Heart and Vascular Health Study is a case-control study of risk 
factors for the development of cardiovascular events, including myocardial infarction (MI) and stroke. All study 
participants were Group Health (GH) members and aged 30-79 years.6  MI and stroke cases were identified 
from hospital discharge diagnosis codes and were validated by medical record review. Controls were a random 
sample of GH members frequency matched to MI cases on age (within decade), sex, treated hypertension, 
and calendar year of identification. Only hypertensive control participants were included in this analysis.  Lipid 
measures were obtained from the GH laboratory results database.  Medication use was ascertained using 
computerized GH pharmacy records.  The HVH data were analyzed in two phases because genotyping was 
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done with two different panels and at two different times. Across both phases, 676 persons of EA descent 
contributed data to this analysis.   
HyperGEN (Hypertension Genetic Epidemiology Network): HyperGEN is a family-based study that looks at 
the genetic causes of hypertension and related conditions in EA and AA subjects.7 HyperGEN recruited 
hypertensive sibships, along with their normotensive adult offspring, and an age-matched random sample. 
HyperGEN has collected data on 2 471 Caucasian-American subjects and 2 300 African-American subjects, 
from five field centers in Alabama, Massachusetts, Minnesota, North Carolina, and Utah.  
JHS (Jackson Heart Study): The Jackson Heart Study is a longitudinal, community-based observational 
cohort study investigating the role of environmental and genetic factors in the development of cardiovascular 
disease in African Americans.  Between 2000 and 2004, a total of 5 301 participants were recruited from a tri-
county area (Hinds, Madison, and Rankin Counties) that encompasses Jackson, MS. Details of the design and 
recruitment for the Jackson Heart Study cohort has been previously published.8-10 Briefly, approximately 30% 
of participants were former members of the Atherosclerosis Risk in Communities (ARIC) study.  The remainder 
were recruited by either 1) random selection from the Accudata list, 2) commercial listing, 3) a constrained 
volunteer sample, in which recruitment was distributed among defined demographic cells in proportions 
designed to mirror those in the overall population, or through the Jackson Heart Study Family Study. 
MESA (Multi-Ethnic Study of Atherosclerosis): MESA is a study of the characteristics of subclinical 
cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) 
and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the 
subclinical disease. MESA researchers study a diverse, population-based sample of 6 814 asymptomatic men 
and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28% African-American, 
22% Hispanic, and 12% Asian, predominantly of Chinese descent. 11 Participants were recruited from six field 
centers across the United States. Four physical examinations (at baseline and at 3 follow-up time points) were 
conducted and the electrocardiography was taken only at baseline. The tenets of the Declaration of Helsinki 
were followed and institutional review board approval was granted at all MESA sites. Written informed consent 
was obtained from each participant. 
PROSPER (Prospective Study of Pravastatin in the Elderly at Risk): All data come from the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER). A detailed description of the study has been published 
elsewhere.12,13 PROSPER was a prospective multicenter randomized placebo-controlled trial to assess 
whether treatment with pravastatin diminishes the risk of major vascular events in elderly. Between December 
1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the 
Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had pre-existing vascular 
disease or increased risk of such disease because of smoking, hypertension, or diabetes. A total number of 
5 804 subjects were randomly assigned to pravastatin or placebo. A large number of prospective tests were 
performed including Biobank tests and cognitive function measurements. 
RS (Rotterdam Study): The Rotterdam study is a prospective population based cohort study comprising 7 983 
participants aged 55 years or older (RS1), which started in 1990.14 In 2000-2001, an additional 3 011 
individuals aged 55 years or older were recruited (RS2). At baseline, participants were interviewed at home 
and were examined at the research center. Since then, participants are followed continuously and re-examined 
during several follow-up examination rounds. Medical information is available of all participants by collaboration 
with the general practitioners and with the pharmacies in the area of Ommoord. The medical ethics committee 
of Erasmus University, Rotterdam, approved the study, and all participants gave informed consent. 
WHI (Women’s Health Initiative): WHI is a long-term national health study that focuses on strategies for 
preventing common diseases such as heart disease, cancer and fracture in postmenopausal women.  A total 
of 161 838 women aged 50–79 years old were recruited from 40 clinical centers in the US between 1993 and 
1998. WHI consists of an observational study (OS) and clinical trials (CT) of postmenopausal hormone 
therapy, calcium / vitamin D supplementation, and dietary modification.15 Study recruitment and exclusion 
criteria have been described previously.15 Recruitment was done through mass mailing to age-eligible women 
obtained from voter registration, driver’s license and Health Care Financing Administration or other insurance 
list, with emphasis on recruitment of minorities and older women.16 Exclusions included participation in other 
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randomized trials, predicted survival < 3 years, alcoholism, drug dependency, mental illness and dementia. 
Study protocols and consent forms were approved by the IRB at all participating institutions.  Medical history, 
medication use, anthropometrics (height; weight; body mass index), and fasting lipid concentrations were 
determined at screening and follow-up visits.16 In this context, women of European ancestry were controls from 
a case-control study of incident coronary heart disease, stroke, venous thromboembolism, and diabetes 
(Genome-wide Association Research Network into Effects of Treatment (WHI CT GARNET),17 while women of 
African ancestry were from the WHI Single Nucleotide Polymorphism Health Association Resource (WHI CT or 
OS SHARe).18 Analyses of non-overlapping WHI CT and OS participant subsets were stratified by availability 
of lipid concentrations measured in serum at only one (Baseline) visit or in plasma at repeated (Core) visits. 
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